NASDAQ:FULC

Fulcrum Therapeutics News Headlines

$11.87
-0.05 (-0.42 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.59
Now: $11.87
$12.08
50-Day Range
$10.94
MA: $12.38
$15.32
52-Week Range
$7.01
Now: $11.87
$22.39
Volume55,864 shs
Average Volume143,298 shs
Market Capitalization$387.82 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94

Headlines

Fulcrum Therapeutics (NASDAQ FULC) News Headlines Today

SourceHeadline
Morgan Stanley Increases Fulcrum Therapeutics (NASDAQ:FULC) Price Target to $12.00Morgan Stanley Increases Fulcrum Therapeutics (NASDAQ:FULC) Price Target to $12.00
marketbeat.com - March 15 at 8:37 AM
Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual ConferenceFulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference
finance.yahoo.com - April 9 at 6:04 PM
Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at Credit Suisse GroupFulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at Credit Suisse Group
americanbankingnews.com - March 29 at 9:28 AM
Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and DevelopmentFulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
finance.yahoo.com - March 24 at 10:53 AM
Fulcrum Therapeutics (NASDAQ:FULC) Now Covered by Analysts at Credit Suisse GroupFulcrum Therapeutics (NASDAQ:FULC) Now Covered by Analysts at Credit Suisse Group
americanbankingnews.com - March 22 at 9:04 AM
Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific ConferenceFulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
finance.yahoo.com - March 18 at 1:02 PM
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Insider Sells $111,729.43 in StockFulcrum Therapeutics, Inc. (NASDAQ:FULC) Insider Sells $111,729.43 in Stock
americanbankingnews.com - March 17 at 5:08 PM
Fulcrum Therapeutics Inc Registered Shs Equal WeightFulcrum Therapeutics Inc Registered Shs Equal Weight
markets.businessinsider.com - March 10 at 1:23 PM
Morgan Stanley Maintains Equal-Weight on Fulcrum Therapeutics, Raises Price Target to $12Morgan Stanley Maintains Equal-Weight on Fulcrum Therapeutics, Raises Price Target to $12
benzinga.com - March 8 at 6:30 PM
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2020 Results - Earnings Call TranscriptX4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 5 at 5:30 PM
Fulcrum Therapeutics Inc Registered Shs BuyFulcrum Therapeutics Inc Registered Shs Buy
markets.businessinsider.com - March 4 at 9:27 PM
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue EstimatesFulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 4 at 1:40 PM
Fulcrum Therapeutics Inc to Host Earnings CallFulcrum Therapeutics Inc to Host Earnings Call
finance.yahoo.com - March 4 at 8:39 AM
Fulcrum Therapeutics Announces CEO TransitionFulcrum Therapeutics Announces CEO Transition
finance.yahoo.com - March 4 at 8:39 AM
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial ResultsFulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 4 at 8:39 AM
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ETFulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET
finance.yahoo.com - February 26 at 7:11 AM
Fulcrum Therapeutics Recognizes Rare Disease Day 2021Fulcrum Therapeutics Recognizes Rare Disease Day 2021
finance.yahoo.com - February 26 at 7:11 AM
What Type Of Shareholders Own The Most Number of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares?What Type Of Shareholders Own The Most Number of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares?
finance.yahoo.com - February 17 at 1:32 PM
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to  Purchase Additional SharesFulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
finance.yahoo.com - January 22 at 7:43 PM
Fulcrum Therapeutics Announces Pricing of Public Offering of Common StockFulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 19 at 10:57 PM
Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific OfficerFulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer
finance.yahoo.com - January 19 at 5:56 PM
Fulcrum Therapeutics Announces Proposed Public Offering of Common StockFulcrum Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 19 at 5:56 PM
Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 ConferenceFulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference
finance.yahoo.com - January 6 at 10:02 AM
Is FULC A Good Stock To Buy Now?Is FULC A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 12:51 AM
Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell DiseaseFulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
finance.yahoo.com - December 9 at 7:17 AM
Heres Why Were Not Too Worried About Fulcrum Therapeutics (NASDAQ:FULC) Cash Burn SituationHere's Why We're Not Too Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Situation
finance.yahoo.com - November 16 at 12:27 PM
Fulcrum Therapeutics Inc Registered Shs OutperformFulcrum Therapeutics Inc Registered Shs Outperform
markets.businessinsider.com - November 12 at 11:21 PM
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q3 2020 Results - Earnings Call TranscriptFulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 5:48 PM
Fulcrum Therapeutics (FULC) Shares March Higher, Can It Continue?Fulcrum Therapeutics' (FULC) Shares March Higher, Can It Continue?
finance.yahoo.com - November 10 at 12:48 PM
Novavax (NVAX) Loss Widens in Q3, Revenues Lag EstimatesNovavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates
finance.yahoo.com - November 10 at 12:48 PM
Fulcrum Therapeutics EPS misses by $0.03, beats on revenueFulcrum Therapeutics EPS misses by $0.03, beats on revenue
seekingalpha.com - November 10 at 7:48 AM
Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial ResultsFulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
finance.yahoo.com - November 10 at 7:48 AM
Why Fulcrum Therapeutics (FULC) Might Surprise This Earnings SeasonWhy Fulcrum Therapeutics (FULC) Might Surprise This Earnings Season
finance.yahoo.com - November 9 at 11:44 AM
Axsomes (AXSM) Q3 Earnings In Line, Pipeline ProgressesAxsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses
nasdaq.com - November 6 at 12:31 PM
Fulcrum Therapeutics Inc Registered Shs hosts conference call for investorsFulcrum Therapeutics Inc Registered Shs hosts conference call for investors
markets.businessinsider.com - November 4 at 5:45 PM
Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and ExpositionFulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
finance.yahoo.com - November 4 at 5:45 PM
Fulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8:00 a.m. ETFulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8:00 a.m. ET
finance.yahoo.com - November 3 at 8:20 AM
Kaskela Law LLC Announces Stockholder Investigation of Fulcrum Therapeutics, Inc. - FULCKaskela Law LLC Announces Stockholder Investigation of Fulcrum Therapeutics, Inc. - FULC
finance.yahoo.com - October 31 at 9:00 AM
Fulcrum Therapeutics Inc Registered Shs OverweightFulcrum Therapeutics Inc Registered Shs Overweight
markets.businessinsider.com - October 16 at 7:46 AM
Fulcrum Therapeutics on go with early-stage study with FTX-6058 for sickle cellFulcrum Therapeutics on go with early-stage study with FTX-6058 for sickle cell
seekingalpha.com - October 5 at 12:00 PM
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell DiseaseFulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
markets.businessinsider.com - October 5 at 12:00 PM
Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and  43rd National Sickle Cell Disease Scientific MeetingFulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting
finance.yahoo.com - September 26 at 2:15 PM
Fulcrum Therapeutics FTX-6058 shows encouraging action preclinical studiesFulcrum Therapeutics' FTX-6058 shows encouraging action preclinical studies
seekingalpha.com - September 25 at 6:20 PM
Fulcrum Therapeutics(NASDAQ:FULC) Share Price Is Down 33% Over The Past Year.Fulcrum Therapeutics'(NASDAQ:FULC) Share Price Is Down 33% Over The Past Year.
finance.yahoo.com - August 18 at 6:45 PM
Fulcrum Therapeutics'(NASDAQ:FULC) Share Price Is Down 33% Over The Past Year.Fulcrum Therapeutics'(NASDAQ:FULC) Share Price Is Down 33% Over The Past Year.
finance.yahoo.com - August 18 at 6:45 PM
Fulcrum Therapeutics, Inc. 2020 Q2 - Results - Earnings Call PresentationFulcrum Therapeutics, Inc. 2020 Q2 - Results - Earnings Call Presentation
seekingalpha.com - August 13 at 5:53 PM
Fulcrum Therapeutics Inc. (FULC) CEO Robert Gould on Q2 2020 Results - Earnings Call TranscriptFulcrum Therapeutics Inc. (FULC) CEO Robert Gould on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 12 at 1:28 AM
Fulcrum under pressure on underwhelming losmapimod data in type of muscular dystrophyFulcrum under pressure on underwhelming losmapimod data in type of muscular dystrophy
seekingalpha.com - August 11 at 9:34 AM
Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
finance.yahoo.com - August 11 at 9:34 AM
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial ResultsFulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
finance.yahoo.com - August 11 at 9:34 AM
Why Earnings Season Could Be Great for Fulcrum Therapeutics (FULC)Why Earnings Season Could Be Great for Fulcrum Therapeutics (FULC)
finance.yahoo.com - August 10 at 11:39 AM
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.